Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Katja Weisel et al.|The Lancet Oncology|2019Cited by 383
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyFederica Cavallo, Antonio Palumbo, Giuseppe Milone et al.|Leukemia|2011Cited by 63
High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55–85Annarita Valeria Piazzolla, Alessandra Mangia, Giulia Paroni et al.|Pathogens|2021Cited by 10